Drug Profile
Research programme: solid tumour therapeutics - PhytoMedical Technologies
Alternative Names: D11BLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Dartmouth College
- Developer PhytoMedical Technologies
- Class Small molecules
- Mechanism of Action DNA intercalators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glioblastoma; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in USA (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 16 Apr 2010 PhytoMedical signs a letter of intent with Shanghai Medicilon to advance D11B